Drug cost-effectiveness analysis in France has evolved.
In France, manufacturers of innovative drugs are required to submit cost-effectiveness analysis and, in some cases, budget impact analysis, which the French Economic and Public Health Committee (CEESP) at the French Health Authority (HAS), use to deliver an economic opinion to the country’s pricing committee. Since 2013, these opinions have fundamentally evolved, and more recently, the methodological framework for the cost-effectiveness analysis at the HAS was updated, with major changes.
Having a good understanding of these changes and their impact is critical to prepare a high-quality submission file and can increase the likelihood of a timely, and successful positive opinion from the CEESP.
Join us to learn about the process leading to an economic opinion, the impact of the July 2020 methodological guidance, and how to choose the best methodology and effectively present it. We will focus on cost-effectiveness analysis for medicinal products and provide insights on:
- The key points of the choice of comparators
- The new guidelines for economic evaluation at the HAS, published in July 2020
- Recent CEESP economic opinions, based on a review between 2014 and 2020
On-Demand Webinar Archive
To access the archived recording of this webinar, visit our webinar channel and complete a one time only form. This will give you access to our entire library of archived webinars.Access Webinar Archive
This program is intended for professionals from pharmaceutical, biotech, and medical device companies involved in the development and submission of economic evaluation dossiers in France, including:
- Health technology assessment (HTA)
- Health economics & outcomes research (HEOR)
- Market access, pricing & reimbursement
Senior Principal, HTA and Value Communications Lead, Health Economics and Outcome Research, ICON
Caroline joined ICON in 2009 and has over 15 years of healthcare experience spanning industry and consulting. Her primary focus is on market access and pricing projects with extensive experience in oncology, haematology, gastroenterology and orphan drugs. She has been involved in projects on health policy, health technology assessment, and public health programs assessment, including disease management. Her activities include due diligences for mergers and acquisitions and licensing.
Fabienne Midy, PhD
Lead Consultant, Health Economics Outcomes and Research, ICON
Fabienne joined ICON in September 2020 as a lead consultant. Fabienne is a health economist, with more than 17 years of professional experience in health economic evaluation and health technology assessment. She has obtained a PhD, the subject of which was the evaluation of quality of life. After five years working in the health economics research field, she worked nearly 17 years at the French Health Authority (HAS). The last seven years of her time at the HAS, she actively participated in the Economic Advice mission analysing industrial files submitted to the CEESP. She was also in charge of the scientific coordination of the methodological guidelines on economic evaluation for HAS (2011 and 2020 version).